DEFA14A: Zimmer Biomet to Acquire Monogram Technologies in $177 Million Deal Plus Contingent Value Rights

Zimmer Biomet Holdings, Inc. has entered into a definitive agreement to acquire Monogram Technologies Inc. for an upfront cash payment of $4.04 per share, plus contingent value rights tied to future product development, regulatory, and revenue milestones.

Summary

• Monogram Technologies Inc. will be acquired by Zimmer Biomet Holdings, Inc. through a merger with its wholly-owned subsidiary, Honey Badger Merger Sub, Inc.
• Each outstanding share of Monogram common stock will be converted into the right to receive $4.04 in cash and one contractual contingent value right (CVR).
• Each outstanding share of Monogram's 8.00% Series D Convertible Cumulative Preferred Stock will receive $2.25 in cash plus accrued but unpaid dividends.
• Each outstanding share of Monogram's Series E Redeemable Perpetual Preferred Stock will receive $100.00 in cash.
• Outstanding stock options will be canceled; vested in-the-money options will receive a cash payment equal to the excess of the cash amount over the exercise price, plus one CVR.
• The total equity value of the transaction is approximately $177 million, with an enterprise value of approximately $168 million.
• The CVRs are non-transferable (except for permitted transfers) and represent the right to receive up to $12.37 per share in cash if certain milestones are achieved through 2030.
• Milestones for CVR payments include: $1.04 for proof-of-concept demonstration (by Jan 31, 2026 or 30 days post-closing), $1.08 for FDA 510(k) clearance of fully autonomous robotic system (by Dec 31, 2027), $3.41 for $156 million in Gross Revenue (2028), $3.41 for $381 million in Gross Revenue (2029), and $3.43 for $609 million in Gross Revenue (2030).
• Partial payments for revenue milestones are possible based on achievement breakpoints (e.g., 50% revenue triggers 5% of milestone payment, 99% revenue triggers 90% of milestone payment).
• A lookback mechanism allows any excess revenue from the Fifth Milestone (2030) to retroactively contribute to achieving the Third and Fourth Milestones.
• The merger is subject to Monogram stockholder approval, HSR Act expiration/termination, and absence of legal restraints.
• Monogram's securities will be delisted from Nasdaq and deregistered under the Exchange Act after the merger closes.
• A termination fee of $11 million is payable by Monogram under certain specified circumstances, such as entering into a superior offer or a change in recommendation by Monogram's Board.
• Certain Monogram stockholders have entered into a voting agreement to support the merger.
• Zimmer, Inc., a subsidiary of Parent, will provide Monogram with a delayed draw loan of up to $15 million if the merger is not consummated between December 1, 2025, and the End Date, with a maturity date of December 1, 2027, and an interest rate of 10.0% (13.0% on default).

Sentiment

Score: 8

Explanation: The document announces a definitive merger agreement with a significant premium and potential upside via CVRs for Monogram shareholders. For Zimmer Biomet, it's a strategic acquisition that enhances its robotics portfolio and is expected to drive future revenue growth and become accretive to EPS, despite short-term neutrality. The tone is highly positive, emphasizing strategic benefits and future potential, though standard risks are disclosed.

Positives

• Monogram shareholders receive an upfront cash payment of $4.04 per share, providing immediate liquidity and a premium.
• The contingent value rights (CVRs) offer Monogram shareholders potential for significant additional cash payments, up to $12.37 per share, tied to future product development, regulatory, and revenue achievements.
• The acquisition expands Zimmer Biomet's robotics portfolio with Monogram's semiand fully autonomous robotic technologies, enhancing its competitive position in orthopedic surgery.
• Monogram's CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology received FDA 510(k) clearance in March 2025, indicating regulatory progress.
• Zimmer Biomet aims to be the first and only company in orthopedics to offer a fully autonomous surgical robot, potentially redefining the standard of care.
• The transaction is expected to contribute to Zimmer Biomet's revenue growth starting in 2027 and be accretive to adjusted earnings per share from 2028 onwards.
• Zimmer Biomet projects a high-single digit return on invested capital (ROIC) by year five, with increasing contribution thereafter.
• The acquisition is expected to improve Zimmer Biomet's robotic knee adoption in the U.S. and expand its global knee offerings.
• The loan agreement provides Monogram with up to $15 million in financing if the merger is delayed, ensuring continued operations.

Negatives

• The CVRs are non-transferable, limiting liquidity for shareholders who receive them.
• There is no assurance that any of the CVR milestones will be achieved, meaning the full potential CVR payment of $12.37 per share may not materialize.
• Monogram is subject to a termination fee of $11 million under certain circumstances, which could be a significant financial burden if the deal falls through due to Monogram's actions.
• The transaction involves significant integration risks, including the possibility that the expected benefits will not be realized or will not be realized within the expected time period.
• The proposed transaction may disrupt Monogram's business and operational relationships, including with customers, vendors, and employees.
• Monogram's management attention may be diverted from ongoing business operations due to the transaction.
• The announcement or consummation of the proposed transaction could negatively affect the market price of Monogram's common stock and its operating results.
• There are unknown liabilities associated with the transaction.
• The loan agreement includes a 13.0% interest rate upon an Event of Default, which is a high cost of capital.

Risks

• Risks related to the satisfaction of closing conditions, including failure to obtain necessary regulatory approvals (e.g., HSR Act clearance).
• Uncertainties as to whether Monogram's stockholders will approve the proposed transaction.
• The possibility that competing offers or acquisition proposals for Monogram will be made.
• The occurrence of any event, change, or other circumstances that could give rise to the termination of the Merger Agreement, including circumstances requiring Monogram to pay a termination fee.
• Risks related to the ability to realize the anticipated benefits of the proposed transaction, including the possibility that expected benefits will not be realized or will not be realized within the expected time period.
• The risk that the businesses will not be integrated successfully.
• Risks relating to changing demand for Monogram's existing products.
• Risks relating to the achievement, in part or at all, of the revenue and other milestones necessary for the payment of any contingent value rights.
• Disruption from the proposed transaction making it more difficult to maintain business and operational relationships, including with customers, vendors, service providers, independent sales representatives, agents or agencies.
• Monogram's ability to attract, motivate, or retain key executives, employees, and other associates.
• Risks related to the proposed transaction diverting Monogram's management's attention from ongoing business operations.
• Negative effects of the announcement of the Merger or the consummation of the proposed transaction on the market price of Monogram's common stock and on Monogram's operating results.
• Significant transaction costs.
• Unknown liabilities.
• The risk of litigation, including shareholder litigation, and/or regulatory actions, including any conditions, limitations, or restrictions placed on approvals by any applicable governmental entities, related to the proposed transaction.

Future Outlook

Zimmer Biomet expects the acquisition to be neutral to adjusted earnings per share in 2025, 2026, and 2027, and accretive in 2028 and beyond. The acquisition is anticipated to contribute to revenue growth starting in 2027 and is projected to generate a high-single digit return on invested capital (ROIC) by year five, with increasing contribution thereafter. Monogram's semi-autonomous TKA robotic technology, which received FDA 510(k) clearance in March 2025, is expected to be commercialized with Zimmer Biomet implants in early 2027. Monogram is also developing a fully autonomous version of the technology with potential for increased safety, efficiency, and outcomes, and additional applications beyond TKA.

Management Comments

• Ivan Tornos, Chairman, President and Chief Executive Officer of Zimmer Biomet, stated: "Monogram's technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation."
• Ivan Tornos also commented: "Zimmer Biomet has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery."
• Benjamin Sexson, Chief Executive Officer of Monogram, stated: "We are thrilled by the opportunity to add our technology to Zimmer Biomet's leading portfolio of surgical robotics, navigation solutions and trusted implants and to benefit from their deep industry expertise and global scale."

Industry Context

This acquisition positions Zimmer Biomet to significantly expand its presence in the rapidly growing orthopedic robotics segment. By integrating Monogram's semiand fully autonomous robotic technologies, Zimmer Biomet aims to offer the most comprehensive and flexible technology ecosystem, catering to diverse surgeon preferences (CT and non-CT, robotic and non-robotic, manual, surgeon-centered, or semito fully autonomous). This move is a strategic response to the increasing demand for advanced surgical solutions and aims to differentiate Zimmer Biomet by potentially being the first to market with a fully autonomous surgical robot, setting a new standard in orthopedic surgery. The acquisition complements Zimmer Biomet's existing ROSA Robotics platform, which is a market leader outside the U.S. and is undergoing significant R&D investment for new product and software applications.

Comparison to Industry Standards

• The acquisition of Monogram's semi-autonomous TKA robotic technology, which received FDA 510(k) clearance in March 2025, positions Zimmer Biomet to compete directly with existing robotic systems in the total knee arthroplasty market, such as Stryker's Mako SmartRobotics and Johnson & Johnson's VELYS Robotic-Assisted Solution.
• Zimmer Biomet's stated goal of becoming the first and only company in orthopedics to offer a fully autonomous surgical robot represents a significant leap beyond current industry offerings, which are primarily surgeon-assisted or semi-autonomous.
• The projected high-single digit return on invested capital (ROIC) by year five for the acquisition suggests a financial performance target that aligns with or exceeds typical benchmarks for strategic acquisitions in the medical technology sector, where ROIC often takes several years to materialize due to integration costs and market adoption curves.
• The CVR structure, with milestones tied to specific product development (proof-of-concept, FDA clearance) and revenue targets ($156M, $381M, $609M), provides a risk-sharing mechanism common in biotech and medical device acquisitions where future product success is uncertain, similar to deals seen with companies like Medtronic or Intuitive Surgical acquiring smaller innovative firms.

Management Changes

Corporate Governance

Legal Proceedings

• Risk of litigation, including shareholder litigation, related to the proposed transaction.
• Monogram will give Parent the opportunity to participate in the defense and settlement of any stockholder litigation against the Company or its directors relating to the Agreement or the Transactions, and will not settle without Parent's prior written consent.

Related Party Transactions

• A Voting Agreement was entered into concurrently with the Merger Agreement between Parent, Merger Sub, and certain stockholders of Monogram (including Benjamin Sexson), obligating them to vote in favor of the merger.
• A delayed draw loan agreement was entered into concurrently with the Merger Agreement between Monogram and Zimmer, Inc., a wholly-owned subsidiary of Parent, for up to $15 million in loans under certain conditions.

Stakeholder Impact

• Shareholders of Monogram Technologies will receive a cash payment and contingent value rights, providing immediate value and potential future upside based on performance milestones.
• Employees of Monogram Technologies will receive offers of employment from Zimmer Biomet or its affiliates, with base salary/wage rates and target annual cash incentive opportunities no less favorable for one year post-closing, and comparable retirement and health/welfare benefits.
• Customers and business partners may experience disruption due to the integration of Monogram into Zimmer Biomet, though the intent is to expand offerings and capabilities.
• Creditors of Monogram will be impacted by the change in ownership and the new loan agreement, which includes provisions for mandatory prepayments upon certain events like a change of control or material financings.

Next Steps

• Monogram to file preliminary and definitive proxy statements with the SEC related to the proposed transaction.
• Monogram to hold a stockholder meeting to vote on the adoption of the Merger Agreement.
• Expiration or termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
• Obtaining any necessary regulatory approvals from specified antitrust authorities.
• Monogram's securities to be delisted from the Nasdaq Stock Market and deregistered under the Securities Exchange Act of 1934 after the Effective Time.
• Zimmer Biomet and a rights agent to enter into the Contingent Value Rights Agreement at or prior to the Effective Time.
• Zimmer Biomet or its affiliates to make written offers of employment to each current employee of Monogram prior to closing.
• Monogram's Board to adopt resolutions to terminate its 401(k) plan and health/welfare benefit plans prior to closing, unless Parent provides written notice otherwise.
• Monogram's Board to adopt resolutions to effect the treatment of Company Options and terminate the Company Equity Plan as of the Effective Time.
• Zimmer Biomet to continue advancing the ROSA platform, with new product and software applications expected between now and 2027, including ROSA Knee with OptimiZe (FDA submission, 510(k) clearance anticipated later this year), ROSA Posterior Hip, and full commercial launch of ROSA Shoulder.
• Commercialization of Monogram's semi-autonomous TKA robotic technology with Zimmer Biomet implants expected in early 2027.
• Potential achievement of CVR milestones: proof-of-concept demo (by Jan 31, 2026), FDA 510(k) clearance (by Dec 31, 2027), and revenue targets for 2028, 2029, and 2030.

Key Dates

Recommendation

Keywords

Orthopedic Robotics, Medical Technology, Merger, Acquisition, Contingent Value Rights, CVR, FDA Clearance, Total Knee Arthroplasty, TKA, Autonomous Robotics, AI-Navigated Surgery, Zimmer Biomet, Monogram Technologies, Healthcare, Surgical Robotics